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Abstract
Background: Although otorrhea occurs commonly in HIV-infected infants, there are few data. We compared the
incidence of otorrhea in infants receiving early vs deferred ART in the Children with HIV Early Antiretroviral (CHER)
trial. Infants aged 6 to 12 weeks of age with confirmed HIV infection and a CD4 percentage greater than or equal
to 25% were randomized to early or deferred ART at two sites in South Africa. Medical records from one study site
were reviewed for otorrhea.
Findings: Data were reviewed from the start of the trial in July 2005 until 20 June 2007, when the Data Safety
Monitoring Board recommended that randomization to the deferred arm should stop and that all infants in this
arm be reviewed for commencing antiretroviral therapy. Infants entered the study at a median of 7.4 weeks of age.
Eleven of 38 (29%) on deferred therapy and 7 of 75 (9%) in the early-therapy group developed otorrhea (risk ratio
3.1, 95% confidence interval (CI) 1.31-7.36; p = 0.01).
Conclusions: Early initiation of antiretroviral therapy is associated with significantly less otorrhea than when a
deferred strategy is followed.
Trial registration: NCT00102960. ClinicalTrials.Gov
Background
Chronic suppurative otitis media (CSOM), usually
accompanied by otorrhea, is a major cause of hearing
impairment in children, especially in developing coun-
tries. Management is either unsatisfactory or very diffi-
cult [1]. Otorrhea typically occurs after perforation of the
tympanic membrane as a complication of acute otitis
media, with subsequent discharge of pus into the external
ear canal. Acute otitis media is hard to diagnose in young
infants due to non-specificity of presenting symptoms
and the difficulty of visualizing the tympanic membrane
[2]. Otorrhea, however, is easy to visualize and does not
require any equipment [1].
The study was a retrospective folder search for otorrhea
identified in the clinical notes and assumed due to a per-
foration of the tympanum, which is the most common
cause. External otitis media was excluded clinically. Otitis
media and otorrhea are World Health Organization
(WHO) stage II events for HIV in children [3]. Both occur
frequently in HIV-infected children [4-6]. Antiretroviral
therapy (ART) was associated with a reduction in otitis
media and CSOM in a retrospective cohort [7].
In a sub-analysis of a prospective randomized strategy
trial, we compared otorrhea in young HIV-infected
infants receiving early versus delayed ART. Infants aged
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6 to 12 weeks of age with confirmed HIV infection and a
CD4 percentage greater than or equal to 25% were
randomized to deferred ART according to South African
guidelines [8] (the deferred-therapy group) or immediate
ART until 1 or 2 years of age (the early-therapy groups),
followed by treatment interruption.
Methods
Background
The Children with HIV Early Antiretroviral Therapy
(CHER) trial is a prospective randomized study evaluating
ART strategies in two centers, the Children’s Infectious
Diseases Clinical Research Unit (KID-CRU), Tygerberg,
Cape Town and the Perinatal HIV Research Unit, Soweto,
South Africa. All infants were confirmed HIV-positive by
polymerase chain reaction (PCR) test. Immunologic cri-
teria for initiating ART in the deferred-therapy group
were a CD4 percentage below 20% or, for children
younger than 12 months, a CD4 percentage below 25% or
a CD4 count below 1000 cells per mm3, according to
WHO guidelines updated in 2006 [9]. ART consisted of
lopinavir/ritonavir, zidovudine and lamivudine and com-
menced at baseline in the early ART group. The primary
outcomes of interest were death and disease progression.
After randomization, infants were seen every 4 weeks
until week 24, every 8 weeks until week 48 and at 12
weekly intervals thereafter. Infants were staged according
to criteria of the Centers for Diseases Control and Preven-
tion with stage C and predefined severe stage B criteria
used for the study end point of disease progression [10].
These criteria approximated WHO stage 3 and 4 [3]. Per-
sistent otorrhea (duration not defined) is a WHO stage 2
event.
The majority of infants were co-enrolled in a compa-
nion study of the 7-valent conjugated Prevnar® Strepto-
coccus pneumoniae vaccine [11]: 36/38 (95%) in the
deferred arm and 65/75 (87%) in the early treatment arm.
All infants also received the conjugated Haemophilus
influenzae B vaccine according to the national immuniza-
tion program and trimethophrim-sulfamethoxazole
(TMP-SMX) prophylaxis.
The CHER study commenced in July 2005. On June
20th, 2007, the Data Safety Monitoring Board (DSMB)
stopped the deferred arm after a median of 40 (interquar-
tile range 24 to 58) weeks on study when initial data
showed that early ART initiation reduced HIV-related
disease progression and mortality by 75% [12].
Study procedures
Data for the present report were from KID-CRU only.
The charts of all infants with CD4% greater than or
equal to 25% enrolled in CHER at KID-CRU from
August 2005 through June 20, 2007 were reviewed.
Otorrhea was classified as mild (a single episode lasting
less than 1 month) or severe (either a single episode last-
ing more than 1 month or more than 1 episode over the
study period). This classification is a modification of that
proposed by Sabella [13]. Although WHO accepts more
than two weeks of otorrhea for a diagnosis of CSOM,
many otorrhinolaryngologists require a duration longer
than 3 months [1]. The Committee for Clinical Trials at
Stellenbosch University approved both the CHER study
and the present sub-analysis (Reference number: M04/07/
033A). The trial was conducted in accordance with the
Helsinki declaration. A parent, usually the mother, or legal
guardian gave written informed consent for each child’s
participation.
Statistical Analysis
All statistical analyses, including the calculation of risk
ratios and confidence intervals (CI), were performed using
STATA version 11.0 (STATA Corporation, College
Station, TX). Chi-square and Fisher exact tests were per-
formed for categorical variables and Wilcoxon rank tests
were performed for continuous variables. All tests were 2-
tailed. Significance level was set at 0.05.
Results
Between August 2005 and February 2007, 113 infants
were enrolled. Thirty-eight were assigned to deferred
therapy and 75 to early therapy. Baseline characteristics
were well matched apart from infants on early therapy
being slightly older (7.7 vs 7.1 weeks) and a trend to bet-
ter weight-for-age-Z score in the deferred group (-0.16 vs
-0.55) (Table 1). The CD4 percentages and counts were
high: CD4% was 35.2% in the early ART group and 35.8%
in the deferred groups, and absolute CD4 count 1835 vs
1728 cells/mm3 respectively. Two infants randomized to
receive early ART had episodes of otorrhea before base-
line and were excluded from the analysis of otorrhea
events. Median (inter-quartile range) follow-up time was
9.6 (7.2-12.8) months. Median (IQR) time on ART was
9.0 (5.5-9.3) months in the early arm and 3.5 (2.3-5.3)
months in the deferred group. Six participants in the
deferred group had otorrhea on ART. Among these,
median time on ART before otorrhea was 4.1 (0.9-4.6)
months. Overall, median CD4 count increased from 1255
cells per mm3 pre-otorrhea to 1352 afterwards: in the
deferred group, CD4 count decreased from 1286 to 1160;
in the early group, CD4 count increased from 1213 to
1774 cells per mm3.
Eighteen infants developed at least one episode of
otorrhea after baseline: 11 of 38 (29%) in the deferred-
therapy group and 7 of 75 (9%) in the early-therapy
groups (risk ratio 3.10, 95% CI, 1.31-7.36; p = 0.01). Eva-
luation for severe otorrhea showed a similar trend, but
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did not reach statistical significance. Seven (18.4%)
in the deferred arm and 6 (8%) in the early ART arm
had severe disease (risk ratio 1.74, 95% CI, 0.97-3.11;
p = 0.10).
Three infants, one in the deferred-therapy group and
two in the early-therapy groups, each had 2 separate
events of otorrhea. In the deferred-therapy group, 40%
of infants had not initiated ART at onset of otorrhea.
Eight infants had otorrhea fluid submitted for culture,
4 from the deferred and 4 on early ART. Two S. pneumo-
nia isolates were from infants on the deferred arm. Of two
Staphylococcus aureus isolates, one was methicillin sensi-
tive and one was resistant. The other isolates included
Pseudomonas, Proteus and Serrattia species and one of
Kelbsiella pneumonia. Five of 7 organisms were resistant
to TMP-SMX.
Discussion
In this prospective randomized study, we showed that
early initiation of ART provided significant protection
against otorrhea compared to deferred ART, initiated on
the basis of either CD4 depletion or progression of HIV
disease. Infants in the deferred arm had 3 times the risk
of developing otorrhea compared with those who started
treatment immediately. Nevertheless, even in the early
therapy group, the incidence was relatively high (9%). In
a cross-sectional survey from Swaziland before the
advent of HIV, the prevalence of otorrhoea in children
attending grade 1 was only 1.3% [14].
Of note is that all infants entered the study being rela-
tively asymptomatic and with high baseline CD4 percen-
tages at a median of 7.4 weeks of age. We documented
a high incidence of otorrhea in the first year of life. Our
study provides additional evidence of the benefits of
ART for infants. Preventing otorrhea in HIV-infected
infants improves their quality of life, preserves hearing
and reduces the burden on the health system. Interest-
ingly, the CD4 counts were relatively high in both
groups, likely due to careful monitoring and ready
access to ART in a trial setting. We infer that ART
must have a qualitative benefit on CD4 functioning.
Our results are similar to those from a retrospective
cohort study from Brazil, which found that ART compris-
ing three antiretrovirals was associated with a significantly
lower prevalence of otorrhea (7.1%) than children receiv-
ing only one or two antiretrovirals (20.8%) (p = 0.02) [7].
The mean age in this study was 6.6 (± 2.5) years, far older
than in our study. We now confirm that their observations
are already noted in the first year of life. In an earlier study
from our unit, the prevalence of otorrhea before the wide-
spread availability of ART was 32%, close to the prevalence
in our deferred-therapy group, and was linked to CD4
depletion [5]. Had we included infants with a CD4 percen-
tage below 25% in CHER, it is likely that we would have
documented a higher prevalence of otorrhea.
The majority of events in the delayed group occurred
on therapy. Possible explanations may include immune
reconstitution inflammatory syndrome as well as better
qualitative antibody production with early antiretroviral
therapy [11].
Our study is strengthened by the fact that it was a
prospective randomized trial. In addition, the study
population represents the broader infant population
accessing ART through the public health system, mak-
ing the results widely generalisable.
There are a number of limitations to our study.
Infants were not evaluated by an otorrhinolaryngolo-
gist. Perforation of the tympanic membrane was not
uniformly documented. Also, we did not consistently
submit otorrhea specimens for bacterial culture or
Table 1 Baseline characteristics of infants receiving early vs deferred ART
Variable Early ART
(n = 75)
Deferred ART
(n = 38)
Total
(n = 113)
P-value
Female (%) 44 (59%) 23 (61%) 67 (59%) 1
Median age (weeks) 7.7 7.0 7.4 0.004
(7.1 to 9.4) (6.5 to 8.5) (6.9 to 9.2)
Median weight for age Z-score -0.55 -0.16 -0.47 0.08
(-1.35 to 0.29) (-1.02 to 0.55) (-1.24 to 0.33)
WHO Stage
I 23 (31%) 14 (37%) 37 (33%) 0.67
II 14 (19%) 5 (13%) 19 (17%)
III 38 (50%) 19 (50%) 57 (50%)
Median CD4 % 35.2 35.8 35.6 0.89
(28.4 to 40.6) (30.0 to 41.8) (28.9 to 40.6)
Median CD4 count (cells/mm3) 1835 1728 1777 0.27
(1362 to 2645) (1174 to 2195) (1325 to 2509)
Continuous data (IQR)
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serotyping of S. pneumonia isolates. We were therefore
unable to evaluate the effect of immunization with the
conjugated pneumococcal vaccine. We have, however,
demonstrated in the companion study to CHER that
early initiation of ART is associated with improved
qualitative function of specific antibodies to serotypes
in vaccine [11]. An intriguing finding in the present
study was that the S. pneumonia isolates were both
from infants where ART was deferred.
Conclusion
Early ART in young HIV-infected infants significantly
reduces the incidence of otorrhea, a condition associated
with much morbidity.
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